Compare ACIW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIW | NAMS |
|---|---|---|
| Founded | 1975 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.7B |
| IPO Year | 1996 | N/A |
| Metric | ACIW | NAMS |
|---|---|---|
| Price | $54.42 | $30.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $62.50 | $46.75 |
| AVG Volume (30 Days) | ★ 982.7K | 977.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.09 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $1,009,780,000.00 | N/A |
| Revenue This Year | $9.67 | $17.96 |
| Revenue Next Year | $7.41 | $540.65 |
| P/E Ratio | $147.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.05 | $21.14 |
| 52 Week High | $60.17 | $42.21 |
| Indicator | ACIW | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.97 |
| Support Level | N/A | $29.23 |
| Resistance Level | N/A | $37.29 |
| Average True Range (ATR) | 0.00 | 1.96 |
| MACD | 0.00 | -0.43 |
| Stochastic Oscillator | 0.00 | 7.49 |
ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.